The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | PRGN-3006 in the treatment of AML and MDS
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses PRGN-3006, a novel chimeric antigen receptor T-cell (CAR-T) therapy, in the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Sallman highlights the mechanism of action of this CAR, its manufacturing process, and concludes by discussing the safety of this product and promising response rates observed in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
